Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Intra-Cellular Therapies ...

    NASDAQ: ITCI · Real-Time Price · USD
    131.87
    0.00 (0.00%)
    At close: Apr 01, 2025, 3:59 PM

    Intra-Cellular Therapies Statistics

    Share Statistics

    Intra-Cellular Therapies has 106.52M shares outstanding. The number of shares has increased by 0.9% in one year.

    Shares Outstanding

    n/a
    		 106.52M

    Shares Change (YoY)

    n/a
    		 0.9%

    Shares Change (QoQ)

    n/a
    		 0.48%

    Owned by Institutions (%)

    n/a
    		 91.2%

    Shares Floating

    n/a
    		 104.82M

    Failed to Deliver (FTD) Shares

    n/a
    		 15,527

    FTD / Avg. Volume

    n/a
    		 0.43%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -115.34 and the forward PE ratio is null. Intra-Cellular Therapies's PEG ratio is 2.28.

    PE Ratio

    n/a
    		 -115.34

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 12.65

    Forward PS

    n/a
    		 4.2

    PB Ratio

    n/a
    		 7.5

    P/FCF Ratio

    n/a
    		 -117.19

    PEG Ratio

    n/a
    		 2.28
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Intra-Cellular Therapies.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 6.36, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 6.36

    Quick Ratio

    n/a
    		 6.23

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 -0.15

    Debt / FCF

    n/a
    		 -0.23

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $791,688.37

    Profits Per Employee

    n/a
    		 $-86,832.56

    Employee Count

    n/a
    		 860

    Asset Turnover

    n/a
    		 0.5

    Inventory Turnover

    n/a
    		 2.17

    Taxes

    Income Tax

    n/a
    		 473K

    Effective Tax Rate

    n/a
    		 -0.64%

    Stock Price Statistics

    The stock price has increased by 80.35% in the last 52 weeks. The beta is 0.46, so Intra-Cellular Therapies's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.46

    52-Week Price Change

    n/a
    		 80.35%

    50-Day Moving Average

    n/a
    		 129.42

    200-Day Moving Average

    n/a
    		 92.67

    Relative Strength Index (RSI)

    n/a
    		 84.54

    Average Volume (20 Days)

    n/a
    		 3,621,742

    Income Statement

    In the last 12 months, Intra-Cellular Therapies had revenue of 680.85M and earned -74.68M in profits. Earnings per share was -0.72.

    Revenue

    n/a
    		 680.85M

    Gross Profit

    n/a
    		 623.89M

    Operating Income

    n/a
    		 -116.72M

    Net Income

    n/a
    		 -74.68M

    EBITDA

    n/a
    		 -116.72M

    EBIT

    n/a
    		 -116.72M

    Earnings Per Share (EPS)

    n/a
    		 -0.72
    Full Income Statement

    Balance Sheet

    The company has 306.95M in cash and 16.98M in debt, giving a net cash position of 289.97M.

    Cash & Cash Equivalents

    n/a
    		 306.95M

    Total Debt

    n/a
    		 16.98M

    Net Cash

    n/a
    		 289.97M

    Retained Earnings

    n/a
    		 -1.69B

    Total Assets

    n/a
    		 1.37B

    Working Capital

    n/a
    		 1.1B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -73.18M and capital expenditures -322K, giving a free cash flow of -73.5M.

    Operating Cash Flow

    n/a
    		 -73.18M

    Capital Expenditures

    n/a
    		 -322K

    Free Cash Flow

    n/a
    		 -73.5M

    FCF Per Share

    n/a
    		 -0.71
    Full Cash Flow Statement

    Margins

    Gross margin is 91.63%, with operating and profit margins of -17.14% and -10.97%.

    Gross Margin

    n/a
    		 91.63%

    Operating Margin

    n/a
    		 -17.14%

    Pretax Margin

    n/a
    		 -10.9%

    Profit Margin

    n/a
    		 -10.97%

    EBITDA Margin

    n/a
    		 -17.14%

    EBIT Margin

    n/a
    		 -17.14%

    FCF Margin

    n/a
    		 -10.8%

    Dividends & Yields

    ITCI does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ITCI is $132, which is 0.1% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $132

    Price Target Difference

    n/a
    		 0.1%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 10
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 38.03

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist